Personalized Cancer Therapy: YES1 Is the New Kid on the Block.
The key bottleneck for the continued success of precision medicine in cancer lies in identifying more targetable genes and associated efficacious clinically usable inhibitors. In this issue of Cancer Research, Hamanaka and colleagues identify YES1 kinase as a targetable cancer target and generate an effective chemical inhibitor for YES1 and demonstrate its efficacy in YES1-amplified tumors.See related article by Hamanaka et al., p. 5734.